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Abstract
Background
Trastuzumab improves survival in HER2+ breast cancer patients, with some evidence of
adverse cardiac side effects. Current recommendations are to give adjuvant trastuzumab
for one year or until recurrence, although trastuzumab treatment for only 9 or 10 weeks has
shown similar survival rates to 12-month treatment. We present here a multi-arm joint analy-
sis examining the relative cost-effectiveness of different durations of adjuvant trastuzumab.
Methods and findings
Network meta-analysis (NMA) was used to examine which trials’ data to include in the cost-
effectiveness analysis (CEA). A network using FinHer (9 weeks vs. zero) and BCIRG006
(12 months vs. zero) trials offered the only jointly randomisable network so these trials were
used in the CEA. The 3-arm CEA compared costs and quality-adjusted life-years (QALYs)
associated with zero, 9-week and 12-month adjuvant trastuzumab durations in early breast
cancer, using a decision tree followed by a Markov model that extrapolated the results to
a lifetime time horizon. Pairwise incremental cost-effectiveness ratios (ICERs) were also
calculated for each pair of regimens and used in budget impact analysis, and the Bucher
method was used to check face validity of the findings. Addition of the PHARE trial (6 months
vs. 12 months) to the network, in order to create a 4-arm CEA including the 6-month regimen,
was not possible as late randomisation in this trial resulted in recruitment of a different patient
population as evidenced by the NMA findings. The CEA results suggest that 9 weeks’ trastu-
zumab is cost-saving and leads to more QALYs than 12 months’, i.e. the former dominates
the latter. The cost-effectiveness acceptability frontier (CEAF) favours zero trastuzumab at
willingness-to-pay levels below £2,500/QALY and treatment for 9 weeks above this thresh-
old. The combination of the NMA and Bucher investigations suggests that the 9-week dura-
tion is as efficacious as the 12-month duration for distant-disease-free survival and overall
survival, and safer in terms of fewer adverse cardiac events.
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Conclusions
Our CEA results suggest that 9-week trastuzumab dominates 12-month trastuzumab in
cost-effectiveness terms at conventional thresholds of willingness to pay for a QALY, and
the 9-week regimen is also suggested to be as clinically effective as the 12-month regimen
according to the NMA and Bucher analyses. This finding agrees with the results of the
E2198 head-to-head study that compared 10 weeks’ with 14 months’ trastuzumab and
found no significant difference. Appropriate trial design and reporting is critical if results are
to be synthesisable with existing evidence, as selection bias can lead to recruitment of a dif-
ferent patient population from existing trials. Our analysis was not based on head-to-head
trials’ data, so the results should be viewed with caution. Short-duration trials would benefit
from recruiting larger numbers of participants to reduce uncertainty in the synthesised
results.
Introduction
Breast cancer is the most common cancer in women in the UK [1] and US [2]. Around 20–
30% of women diagnosed with early-stage breast cancer have tumours over-expressing the
human epidermal growth factor receptor 2 (HER2) protein, and/or exhibiting HER2/neu gene
amplification [3]. In women whose tumours are HER2-positive (HER2+) and therefore more
aggressive, addition of trastuzumab has been found to lead to significantly increased disease-
free and overall survival [4,5,6]. The budget impact of trastuzumab is high [7], mostly due to
the drug’s high cost, and the most serious adverse effect observed is cardiac dysfunction [8,9].
The optimum treatment regimen for trastuzumab is still being explored, including optimal
duration and timing of administration, with which chemotherapy/ies, and in what order
[10,11].
In the UK, trastuzumab is licensed for the treatment of early breast cancer, to be given
3-weekly after chemotherapy for one year or until progression [7,12]. The manufacturer’s ini-
tial marketing authorisation application to NICE focused on data from the European HERA
trial [13] and the North American N9831 and B31 trials of long-duration (12 months’) trastu-
zumab [14,15,16]. However, there is also evidence regarding the efficacy of a shorter regimen
from the FinHer trial [17,18], which found that 9 weeks’ trastuzumab produced improved dis-
tant-disease-free survival (DDFS) over zero trastuzumab in the subgroup of HER2+ patients,
and from the E2198 trial [19,20], which found that disease-free and overall survival (DFS and
OS) were equivalent in the 10-week and 14-month arms.
Duration of trastuzumab treatment is expected to have an impact on both costs and clinical
outcomes, so the aim of this paper was to examine the relative cost and effectiveness of differ-
ent durations of adjuvant trastuzumab, using the results of all eight adjuvant trastuzumab in
early breast cancer trials published to date that compare different adjuvant trastuzumab dura-
tions. These are: B31 [14], BCIRG006 [21], E2198 [20], FinHer [18], HERA [13], N9831 [14],
PACS-04 [22], and PHARE [23], published as seven analyses (B31 and N9831 were analysed
jointly by the original investigators [14]).
To determine which trials’ data could appropriately be included in the CEA model, network
meta-analysis (NMA) was used, then the CEA was run as a multi-arm joint analysis using the
trastuzumab durations highlighted as appropriate for inclusion by the NMA. We also used the
absolute per-arm costs and outcomes from the CEA to calculate pairwise ICERs to compare
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the results of our multi-arm joint analysis to the results of existing pairwise analyses, in order
to investigate the face validity of our work. Finally, to further corroborate our findings, the
Bucher method was used to indirectly compare the survival and adverse event hazard ratios of
different non-zero durations of trastuzumab, providing confidence intervals to indicate
whether any differences found are statistically significant.
Methods
Trial identification
An initial set of eligible trials published up to February 2010 was identified in the 2012
Cochrane Review, “Trastuzumab containing regimens for early breast cancer” [10], which
reported a systematic review of randomised controlled trials (RCTs) “comparing the efficacy
and safety of trastuzumab alone, or in combination with chemotherapy, or no treatment, or
standard chemotherapy alone, in women with HER2-positive early breast cancer, including
women with locally advanced breast cancer”. Further electronic searches were performed
to identify additional RCTs published up to January 2016, using keyword searches (com-
binations of “trastuzumab”, “Herceptin”, “(early) breast cancer” and “adjuvant”) of Web
of Science Core Collection Citation Indexes (https://www.webofknowledge.com/ –all data-
bases), the main clinical trial registries associated with the US (clinicaltrials.gov), EU (www.
clinicaltrialsregister.eu), and the WHO (www.isrctn.com), and the grey literature. Search
results were screened by one author, who applied the same inclusion/exclusion criteria used in
the Cochrane Review to identify and select eligible RCTs, with final inclusion decisions based
on full-text assessments.
Network meta-analysis
Four different durations of trastuzumab have been investigated in clinical trials: zero, short (9
or 10 weeks), medium (6 months), and long (12 or 14 months). The aim of this analysis was to
synthesise as much information as possible from the published studies to be included in the
CEA model. To do this, we examined the published results and used network meta-analysis
(NMA, also called mixed treatment comparison or multivariate meta-analysis) [24] to deter-
mine which trials’ data could be combined together in the CEA. The same stringent criteria
governing appropriate trial inclusion in pairwise meta-analysis [25,26] also apply to network
meta-analysis (NMA) [24]. For NMA results to be meaningful, the transitivity assumption
states that all trials included in the network must be “jointly randomisable” [27], i.e. it would
theoretically be possible for the trials to be considered part of one super-trial, where all patients
who were involved could potentially have been randomised to any of the arms, implying that
the exclusion/inclusion criteria and timing of randomisation are comparable across included
trials. Table 1 gives information regarding these points for the seven published sets of results
listed above, and some of these characteristics are also summarised in the Gantt chart in S1
Fig. Although there are eight trials, the results of trial B31 and N9831 were analysed and pub-
lished jointly by the original investigators due to similarities in the trials’ design, hence there
are seven sets of results.
Categorisation of trials. We categorised trials into jointly randomisable networks, taking
into consideration randomisation timing, differences in timing of trastuzumab administration,
and differences in endpoints, i.e. distant-disease-free survival (DDFS) or disease-free survival
(DFS) (referred to jointly as (D)DFS). The distinction between types of survival endpoints is
important because DDFS includes only metastasis and death, whereas DFS additionally in-
cludes ipsilateral/local, locoregional and contralateral recurrences, as well as new non-breast
tumours in all DFS-reporting studies except PACS-04. Information on these points is given in
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Table 1. Authors of original publications reporting only DFS were contacted to request break-
downs by recurrence type to allow DDFS event rates to be used for all trials, but no responses
were received. Differences in timing of administration of trastuzumab focused on whether the
administration was concomitant with or sequentially after taxane, as it is understood that con-
comitant administration with taxane carries significant survival benefits [28].
We have excluded some arms on the basis that certain treatments would not be offered in
the UK: the vinorelbine arm of the FinHer trial was excluded as it is not recommended by NICE,
and the 2-year arm of the HERA study was omitted as there is no suggestion that the length of
trastuzumab duration should be increased [29]. The 12-month sequential arm of the N9831
study [30] was not included as it was omitted from the published joint analysis of 12-month con-
comitant trastuzumab vs. zero trastuzumab in the N9831 and B31 studies [14] because the B31
trial did not have a corresponding 12-month sequential arm. In order therefore to avoid having
two separate nodes that both contained patients from the N9831 12-month concomitant arm in
the network, we omitted the comparison of the N9831 12-month sequential and concomitant
arms [30].
When taking into consideration the differences in treatment modalities, and according to
the features listed in Table 1, eleven separate treatment categories are identified, and these
along with their connectivities are shown in Fig 1. The 11 categories (nodes) are split into four
networks as follows: the PHARE trial forms a 2-node network by itself; the E2198 trial forms a
second 2-node network; the HERA, PACS-04, and B31/N9831 trials form a 3-node network;
and the BCIRG006 (three arms) and FinHer trials form a 4-node network. All lines represent a
single trial connecting the two arms, except for the heavier line between nodes 2 and 4, which
represents two trials making this comparison; the size of the blue dot at each node represents
numbers of patients. Note that all sets of results also report OS and number of symptomatic
cardiac events as well as either DFS or DDFS.
Fig 1. Full 11-node map, showing the four distinct jointly randomisable networks made up of the
different regimens, characterised by trastuzumab duration, timing of administration, and type of
disease-free endpoint reported. (Key: 14m = 14 months’ trastuzumab; 12m = 12 months’ trastuzumab;
6m = 6 months’ trastuzumab; 10 = 10 weeks’ trastuzumab; 9w = 9 weeks’ trastuzumab; gap = 3-month gap in
trastuzumab administration; con = given concomitantly with taxane; seq = given sequentially with taxane;
mixed = results were not broken down by administration; at R = trastuzumab begun at randomisation; later =
trastuzumab begun some months after randomisation; ddfs = distant disease-free survival; dfs = disease-free
survival; os = overall survival.).
doi:10.1371/journal.pone.0172731.g001
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Ranking of treatment regimens. Decisions made regarding categorisation of trial arms
into network nodes are tested by ranking the arms included in a network in order of which is
“best” for a given outcome measure. This ranking is expressed as the likelihood (i.e. area under
the cumulative probability curve) that a given arm in a network is the “best” for that particular
outcome, i.e. reports the fewest events (deaths, onsets of metastasis, or symptomatic cardiac
events). The arm with the highest probability of being best for that outcome is ranked first,
and so on.
Stata 14’s mvmeta command [31] was implemented via the network package [32]. The
main NMA command used was networksetup d e, where d is the number of events and e
the number of person-years. Input values for the trial arms are given in Table 1. The sucra
command (“surface under the cumulative ranking curve”) calculates the area under the cumu-
lative probability curve and ranks the regimens in order of efficacy according to each outcome
measure.
Cost-effectiveness model
Decision analytic modelling was used, to allow: utilities, costs, trial event data and other inputs
collected from the published literature and other publicly available sources to be synthesised;
costs and effects to be modelled beyond the observed timeframes of the trials; and the effects of
uncertainty about the value of input parameters to be examined via sensitivity analyses. The
cost-effectiveness model was written in Microsoft Excel 2007.
The model structure was determined after the NMA had been completed, as the decision
regarding which trials to include in the CEA informed the choice of disease states, upon which
are based all other decisions regarding state utilities, costs and transition probabilities to be
used in the CEA model. Therefore we briefly outline one aspect of the NMA’s findings here to
allow discussion of the CEA methodology.
The results of the NMA showed that the only jointly randomisable network with more than
two trastuzumab durations was BCIRG006/FinHer (nodes 4, 5, 8, and 9 in Fig 1). We com-
bined BCIRG006’s two 12-month nodes into a single node in the CEA despite apparent dif-
ferences in timing of trastuzumab (see Table 1), since the original trial team reported that
survival rates in these two arms are in fact not statistically significantly different[21] and we
tested this assumption using the SUCRA command and via other sensitivity analyses described
below. These trials reported DDFS and OS events, meaning that the Markov states used in the
CEA were distant disease free (DDF), metastatic disease, and dead. The data included in the
CEA’s three arms were therefore: (i) zero trastuzumab (FinHer’s docetaxel subgroup and
BCIRG006); (ii) 9 weeks’ adjuvant trastuzumab (FinHer’s docetaxel subgroup); and (iii) 12
months’ adjuvant trastuzumab (BCIRG006’s two 12-month arms: TCH and AC-TH, see S1
Fig). UK costs and breast cancer monitoring patterns were used, adopting the English National
Health Service (NHS) payer perspective.
Year 0 of the CEA model began with administration of trastuzumab. Five-year survival data
from FinHer [18] and BCIRG006 [21] were used to populate the decision tree and the results
were extended to the lifetime horizon via a Markov model with quarterly cycles. The simula-
tion used a cohort of 100 patients per arm of the decision tree at Year 0 (see Fig 2A). After 5
years, the patient cohort moved from the decision tree into the Markov model, with the pro-
portion of patients in each health state in the Markov model at the beginning of year 5 deter-
mined by the proportion of patients in each arm of the decision tree at the end of year 4 (see
Fig 2B).
Markov structure, states and transition probabilities. The Markov model included
5-year tunnel states up until 25 years from the start of trastuzumab administration, to allow for
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age-related changes in utility weights [34] and transition probabilities for all-cause mortality
[35]. The probabilities of progression from disease-free to distant disease, and from distant dis-
ease to death, were taken from a previously published CEA based on the FinHer trial data [36]
as this analysis provided appropriate Markov transition probabilities for this patient group,
corresponding to the specific health state transitions in our three-state model. Costs and utili-
ties were applied to patient cohorts at the beginning of each cycle. It was assumed that the
probability of developing metastatic disease was the same regardless of trastuzumab treatment
history [37], and that this risk decreased gradually to zero by year 20. Those developing meta-
static disease did not return to the DDF state. The probability of death after metastasis was
derived from the literature [38]. The structure of the Markov model is shown in Fig 2B and all
inputs are listed in S1 Table. Patients entered the decision tree aged 52 years and the lifetime
horizon used was 48 years, up to a mean age of 100 years.
Utilities. Utility values for the health states were derived from regression analyses pub-
lished as part of a recent systematic review of utilities for breast cancer patients [39]. Upper
and lower limits were derived from the highest and lowest values in the regression analysis
[39]. Patient groups were sub-divided into those that suffered a symptomatic cardiac event
and those that did not, and the utility weight of the former was modified during the decision
tree by a multiplier of 0.60 [40,41] for a mean time period of 3 months (range 1–6 months)
[37]. The utility values for the decision tree arms “metastatic disease” and “dead” were calcu-
lated assuming that the event, namely metastatic disease onset or death, depending on the
arm, occurred at a point chosen to be halfway through the decision tree, i.e. 2.5 years after the
start. Sensitivity bounds where the transition instead occurred at 0.5 or 4.5 years were investi-
gated to test the validity of this decision. The utility applied to the decision tree arm “dead”
assumes on average that the people who die are DDF for 1.25 years, have metastatic disease for
Fig 2. (a) Decision tree schematic showing pathway covered by the CEA’s 5-year decision tree; (b) Markov
model schematic showing model structure used from year 5 onwards.
doi:10.1371/journal.pone.0172731.g002
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1.25 years, and then die at 2.5 years and these assumptions were also tested. These values and
all other inputs are summarised in S1 Table.
Costs for monitoring, recurrence and death. Monitoring and other treatment costs were
taken from 2013–14 NHS reference costs. Calculations of decision-tree arm costs used the
same assumptions as those described above for the utility weights. DDF patients attended
breast cancer clinic for three years or until metastasis. No costs were included for procedures
or drugs common to all arms, which included chemotherapy. Cardiac monitoring patterns
and costs were included according to trial protocols. In the FinHer trial, one patient who
received trastuzumab, and two who did not, suffered symptomatic heart failure. It was not
reported which chemotherapy agent these patients had received (docetaxel or vinorelbine), so
we assumed they were split evenly between the two chemotherapy arms. Numbers of cardiac
events recorded in both trials are given in Table 1. The reference cost year was 2013–14,
adjusted where required using the HCHS Pay and Price Inflation Indices [42].
Trastuzumab costs. The dosing schedules in each arm of the model were according to the
respective trial protocol. NHS reference costs for procurement and delivery of expensive che-
motherapy regimens were used. The standard of care was updated in 2013 by NICE [43] to
include subcutaneous (SC) administration as well as intravenous (IV), but the difference in
price is small, so no corresponding sensitivity analysis has been performed (the SC regimen
costs 1% more than the average cost for the IV regimen over 12 months, and 7% less over 9
weeks; British National Formulary). It is possible that there may be a reduction in the price of
trastuzumab at some point in the next few years due to Herceptin’s (brand name of trastuzu-
mab) patent expiry (Europe in 2014, USA in 2019). However, any reduction in the price would
not be expected to take effect for at least 7–8 years after patent expiry, with uncertain impact
on the market share of Herceptin since this depends on the production of reliable and accept-
able generic versions [44].
Discounting. The base case annual discount rate used for both costs and outcomes was
3.5% [45], with bounds of 0% and 7%. Annual discount rates were adjusted to reflect the
monthly cycles using Eq 1:
monthly rate ¼ ðð1þ annual rateÞ1=12Þ   1: ð1Þ
Sensitivity analyses. One-way deterministic sensitivity analyses were undertaken to
investigate the effect that variation in each individual input parameter has on the overall
results. In addition to this, joint Bayesian probabilistic sensitivity analyses (PSAs) were con-
ducted, varying all input parameters simultaneously over 5,000 simulations, and using beta
prior distributions for all proportions, rates and utilities; and gamma prior distributions for all
costs. The alpha and beta parameters for the transition probabilities’ prior distributions were
taken from the previously published Finnish CEA [36], and the method of moments was used
to estimate alpha and beta for all other parameters based on their upper and lower limits dis-
cussed above [46]. Net monetary benefit (NMB) was calculated for a range of values of willing-
ness to pay (WTP) for a quality-adjusted life-year (QALY), using Eq 2.
NMB ¼ ðQALYs WTP per QALYÞ   Cost ð2Þ
The 5,000 simulations were used to construct cost-effectiveness acceptability curves
(CEACs), which show the probability of each arm being the most cost-effective at a given
WTP. A cost-effectiveness acceptability frontier (CEAF) was generated to show the highest
NMB at each WTP, indicating the ranges of WTP for which each arm was most cost-effective
[47]. The CEA model and corresponding probabilistic sensitivity analyses were also run using
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each 12-month arm of the BCIRG006 study separately, to test whether the cost-effectiveness
results were robust to the combination of the two 12-month arms into one.
Bucher indirect comparison method
This analysis was done to corroborate the results of the CEA regarding the indirect compari-
son of the 9-week and 12-month regimens. The Bucher indirect comparison method used the
OS hazard ratios that were modelled and published by the original trial teams: 9 weeks’ vs.
zero trastuzumab [18] and 12 months’ vs. zero trastuzumab [21], with two HRs for the latter,
one corresponding to each 12-month arm. The resultant calculated hazard ratios gave an indi-
rect comparison of the relative efficacy of 12 months’ and 9 weeks’ trastuzumab in terms of OS
and DDFS, with a 95% confidence interval.
Pairwise comparisons
Besides the joint three-way comparison in the CEA described above and summarised in the
CEAF, we also used the absolute values for each arm to calculate the pairwise incremental
cost-effectiveness ratios (ICERs) comparing the three regimens using Eq 3, and compared
these to other published ICERs for these pairs. This is an important face-validity test as work
published by other groups has compared 9 weeks’ and zero trastuzumab [36, 48, 49, 50], and
12 months’ and zero trastuzumab [9,51] as pairwise comparisons only.
ICER ¼
cost of new regimen   cost of old
QALYs for new regimen   QALYs for old
ð3Þ
Budget impact of switching
Finally, we examined the expected budget impact over one year of switching from the cur-
rently approved 12-month regimen to the 9-week regimen, which was expected to be consider-
able due to the high cost of trastuzumab [7]. This model used breast cancer incidence rates in
England published for 2014 [1] with appropriate ineligibility reductions [7], and the calculated
difference in costs per patient on using the shorter regimen instead of the longer, according to
the CEA model discussed in this paper.
Results
Network meta-analysis
Of the 7 published sets of results, 3 reported OS, DDFS and numbers of cardiac events
(BCIRG006 [21], FinHer [18] and PHARE [23]), and 4 reported OS, DFS and numbers of car-
diac events (B31/N9831 [14], HERA [33], PACS-04 [22] and E2198 [20]). Note that the latest
published results were used in all cases except for two: in HERA, patients were allowed to cross
over from the zero arm to the 12-month arm after the first interim analysis, hence we used the
2-year follow-up results here [33] to avoid contamination present in the 4-year results [52];
and the latest publication for B31/N9831 did not report numbers of symptomatic cardiac
adverse events so could not be used [15]. Of the trials that included a “long” arm (12 or 14
months), three administered trastuzumab concomitantly with taxane (BCIRG006 [21], B31/
N9831 [14] and E2198 [20]), two gave it sequentially after taxane (HERA [33] and PACS-04
[22]), and one allowed both timings of administration to take place and reported only aggre-
gated results (PHARE [23]). These and other points that distinguish between the different
studies are given in Table 1, and the resultant separate networks combining comparable arms
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are shown above in Fig 1. A Gantt chart summarising the administration timings and other
features of the arms is given in S1 Fig. Using these classifications, the only jointly randomisable
network that contained more than one non-zero trastuzumab arm was the BCIRG006/FinHer
network (see Fig 1); the randomisation timings and other features including choice of end-
point reported were compatible, therefore their results were used in the CEA.
The treatment arms in the BCIRG006/FinHer network were ranked in terms of the
reported outcome measures (OS, DDFS and number of symptomatic adverse cardiac events)
and the areas under the cumulative probability curves calculated via the SUCRA command are
shown in Table 2. In terms of both DDFS and OS, the 9-week arm was preferred (95.9% and
85.9% chance of being the best regimen regarding each outcome, respectively) and, in terms of
cardiac events, the zero and 9-week arms are ranked almost in joint first place (47.9% and
47.0% respective likelihoods of providing the best outcome in terms of lower numbers of car-
diac events).
We attempted to include the 6-month arm from PHARE in the CEA by forming a network
where the 12-month arm of PHARE and the 12-month arms of BCIRG006 were combined
in the same network node. However, the PHARE trial could not be considered sufficiently
similar to the BCIRG006 and FinHer trials for this combination to take place due to selection
bias introduced due to late randomisation. Most trials randomised patients before starting che-
motherapy and some waited until chemotherapy had finished (HERA and PACS-04). The
PHARE trial waited until patients had received both chemotherapy and 6 months of trastuzu-
mab, before being randomised to either receive a further 6 months’ trastuzumab or to stop
receiving it (see Table 1 and S1 Fig). As patients must have already survived to this point and
been eligible for a further 6 months of trastuzumab before being randomised, we tested to see
whether this led to PHARE patients being at lower risk of cardiac events than those recruited
to other trials. As Table 3 shows, cardiac event results for the postulated 4-node network
including PHARE, BCIRG006 and FinHer are that the 6-month arm has the highest probabil-
ity of favourable cardiac outcomes (94.4%), followed by the 9-week arm (5.6%), and then the
zero and 12-month arms are worst (0.0%). This did not pass face-validity checks, as it did not
seem plausible that there could be a benefit in terms of fewer cardiac events when using 6
Table 2. SUCRA rankings for BCIRG006/FinHer network.
DDFS (distant disease-free survival) events
Treatment
duration
Area under cumulative probability
curve
Probability that this treatment duration is
best
Rank
Zero 0.5 0.0% 3.0
9 weeks 97.2 95.9% 1.1
12 months 52.0 4.1% 2.0
OS (overall survival) events
Treatment
duration
Area under cumulative probability
curve
Probability that this treatment duration is
best
Rank
Zero 2.2 0.0% 3.0
9 weeks 92.3 88.9% 1.2
12 months 55.5 11.1% 1.9
Cardiac events
Treatment
duration
Area under cumulative probability
curve
Probability that this treatment duration is
best
Rank
Zero 71.9 47.9% 1.6
9 weeks 55.0 47.0% 1.9
12 months 23.1 5.1% 2.5
doi:10.1371/journal.pone.0172731.t002
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months’ trastuzumab, compared to using it for either 9 weeks or 12 months. If PHARE was
omitted, however, there was no discernible difference between zero and short duration of
treatment for the probability of cardiac events (47.9% and 47.0%, respectively). Therefore,
PHARE participants cannot be regarded as having been recruited from the same patient popu-
lation as those in BCIRG006 and FinHer, given the lower risk of cardiac events in the PHARE
study, and PHARE cannot be included in the CEA.
Cost-effectiveness model
The per-arm probabilistic results for the BCIRG006/FinHer cost-effectiveness model are given
in Table 4. At a willingness to pay (WTP) £30,000 per QALY gained, i.e. the upper end of the
generally accepted NICE threshold for cost per QALY gained (£20,000 to £30,000/QALY), 9
weeks has the highest NMB (£276,600 per patient over a lifetime), followed by zero trastuzu-
mab, then 12 months. The zero arm had the lowest cost and resulted in fewest QALYs. The
Table 3. SUCRA rankings for network including BCIRG006, FinHer and PHARE.
DDFS (distant disease-free survival) events
Treatment
duration
Area under cumulative probability
curve
Probability that this treatment duration is
best
Rank
Zero 18.6 0.0% 3.4
9 weeks 97.5 95.5% 1.1
6 months 16.3 0.2% 3.5
12 months 67.5 4.4% 2.0
OS (overall survival) events
Treatment
duration
Area under cumulative probability
curve
Probability that this treatment duration is
best
Rank
Zero 20.8 0.0% 3.4
9 weeks 93.1 88.5% 1.2
6 months 16.3 0.3% 3.5
12 months 69.9 11.1% 1.9
Cardiac events
Treatment
duration
Area under cumulative probability
curve
Probability that this treatment duration is
best
Rank
Zero 16.8 0.0% 3.5
9 weeks 24.4 5.6% 3.3
6 months 98.1 94.4% 1.1
12 months 60.7 0.0% 2.2
doi:10.1371/journal.pone.0172731.t003
Table 4. Lifetime horizon probabilistic (n = 5,000) net monetary benefit per patient (WTP = £30,000/
QALY), total cost and total QALYs per patient per arm (mean and 95% CI of simulation results).
Arm NMB per patient (WTP = £30,000/QALY) Total cost per patient Total QALYs per patient
Zero £238,882 £20,552 8.6
(£165,614 to £312,151) (£15,269 to £25,835) (6.4 to 10.9)
9 weeks £276,600 £23,662 10.0
(£190,568 to £362,632) (£19,443 to £27,881) (7.3 to 12.7)
12 months £228,185 £46,859 9.2
(£147,285 to £309,085) (£39,311 to £54,406) (6.7 to 11.6)
WTP = willingness to pay; QALY = quality-adjusted life-years; CI = confidence interval; NMB = net monetary
benefit
doi:10.1371/journal.pone.0172731.t004
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95% confidence intervals for the numbers of QALYs in each arm calculated from the simula-
tion results all overlap (see Table 4), indicating there is no difference in QALYs among the
arms using Monte Carlo error. When considering the costs per arm, the 95% confidence inter-
vals (CIs) for the costs of the zero and 9-week arms do overlap with each other, suggesting
there is no difference, but neither overlap with the 95% CIs of the 12-month arm, suggesting
that there is a difference in costs on using the 12-month regimen using Monte Carlo error.
Pairwise comparisons
In the pairwise comparison of 9 weeks’ vs. 12 months’ trastuzumab, the shorter regimen domi-
nates the longer, since it costs less and results in more QALYs. The 9-week regimen results in
0.8 more QALYs per patient than the 12-month, with a cost saving of £23,197 per patient. Pair-
wise comparisons of each duration to zero trastuzumab gave ICERs of £50,559 per QALY
gained from using 12-month trastuzumab instead of zero, and £2,286 per QALY gained from
using 9-week trastuzumab instead of zero. Any differences in the pairwise ICERs discussed
here compared to those obtained using the values given in Table 4 are due to rounding.
Budget impact of switching
In 2014 in England, 46,085 new breast cancer cases in women were reported [1], of which 70%
are likely to respond to adjuvant treatment, and 22% of these will have HER2+ tumours [7],
meaning that an additional 7,097 women per year could benefit from being given trastuzumab.
According to current exclusion criteria, approximately 20% of these women would be ineligi-
ble for trastuzumab use, leaving 5,678 patients. Considering the impact on costs and effects of
switching from the current 12-month regimen to the shorter 9-week regimen implies cost sav-
ings and a gain in QALYs, i.e. the short regimen dominates the long. The cost saving would be
£132 million for this cohort of patients in England at 2014 prices and incidence rates, with a
corresponding gain of 4,773 QALYs.
Bucher indirect comparison method
Variation in OS and DDFS were found to be the second strongest drivers of differences in
QALYs in the model, after variation in the Markov utility scores. Given the strength of the
cost-effectiveness findings for 9 weeks compared to 12 months, we used Bucher analysis [53]
to determine whether there were real significant differences in OS and DDFS between the
12-month and 9-week regimens, and test the hypothesis that the difference in QALYs is an
artefact in the construction of the model, rather than the result of a true difference. The hazard
ratio of 9 weeks vs. 12 months was calculated indirectly under two possible scenarios for each
endpoint, one for each of the 12-month vs. zero hazard ratios reported for two 12-month arms
in BCIRG006. The HRs for OS and DDFS are reported in Table 5 and are all smaller than 1,
Table 5. Hazard ratios for indirect pairwise comparison of 12 months vs. 9 weeks, via the Bucher
method.
FinHer, BCIRG006 (TCH) FinHer, BCIRG006 (AC-TH)
OS, 9w vs. 12m; HR (95%CI) 0.55 (0.17 to 1.79) 0.67 (0.20 to 2.20)
DDFS, 9w vs. 12m; HR (95%CI) 0.43 (0.15 to 1.21) 0.50 (0.18 to 1.41)
TCH = BCIRG006 arm comprising docetaxel, carboplatin and 12 months’ trastuzumab; AC-TH = BCIRG006
arm comprising doxorubicin and cyclophosphamide followed by docetaxel and 12 months’ trastuzumab;
OS = overall survival; DDFS = distant disease-free survival; 9w = 9 weeks; 12m = 12 months; HR = hazard
ratio; CI = confidence interval.
doi:10.1371/journal.pone.0172731.t005
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favouring 9 weeks, but not significantly smaller, suggesting an important level of uncertainty
in the results, potentially due to the small patient numbers in the FinHer trial. The E2198
study, published in 2015, compared 10 weeks’ and 14 months’ trastuzumab treatment, and
also found no significant difference between the short and long regimens [20], potentially also
due to small patient numbers.
Sensitivity analysis
Assumptions regarding input parameters were tested using deterministic one-way sensitivity
analysis. Those inputs whose variation led to instability in the results were: variation in the
Markov utility scores, potentially due to the large ranges available for these utility scores (see
S1 Table); and variation in the proportions of patients in each state at the end of the decision
tree, i.e. the OS and DDFS associated with each regimen. The relative sizes of each arm’s
NMB were stable to variation in all other input parameters and assumptions. Additional sensi-
tivity analysis was conducted to test the stability of the model when treating as separate each
12-month arm from the BCIRG006 trial. The means and 95% CIs for the separate 12-month
arms (see S2 Table) are very similar to those in Table 4 for the combined 12-month arm, and
considerations of the Monte Carlo error when comparing these to the zero and 9-week results
in Table 4 lead to the same conclusions as for the combined 12-month arm. Different values
for the OS and DDFS for each arm were tested to see how these changes affected the NMB. For
the NMB of the 12-month arm to be as high as that of the 9-week (£276,600 per patient over
the lifetime horizon, assuming no change in the 9-week survival rates), the 12-month survival
rates must be such that the proportions of patients at the beginning of year 5 fall into the dis-
ease categories with the following split: 99% DDF, 1% metastatic, and zero dead. Similarly, if
the 9-week patient proportions at year 5 are the same as in the 12-month arm (i.e. 81.4% dis-
tant-disease-free, 8.9% metastatic, 9.6% dead), then the NMB for the 9-week arm is £247,588
per patient, i.e. it is still preferred over both the zero and the 12-month arms (compare to
NMB values in Table 4).
Probabilistic sensitivity analysis was performed and the results are shown in CEACs and
the CEAF, presented in Fig 3. The zero arm has the highest probability of being cost-effective
for a WTP less than £2,500 per QALY gained. For all WTP levels above £2,500/QALY, tested
up to £150,000/QALY, 9 weeks has the highest probability of being cost-effective. The CEACs
are calculated using the points of the absolute costs and effects plane, which is given in S3 Fig.
This plot shows the spread of possible values for each arm when considering the joint uncer-
tainties among all inputs, and shows that this uncertainty leads to considerable overlap in
numbers of QALYs gained between all arms, and a clear distinction in costs between the zero/
9-week arms and the 12-month arm, in agreement with the lack of overlap of the 95% confi-
dence intervals for the NMBs in Table 4. The three red dots indicate the deterministic values
for the absolute QALYs and absolute costs for each arm. Note that as there are three arms and
not two, because S3 Fig does not show the incremental costs and effects; instead it shows abso-
lute values.
Discussion
This study considered the relative cost-effectiveness of 9-week and 12-month trastuzumab
treatment regimens via multi-arm joint analysis, using NMA to aid in selection of studies for
inclusion in the CEA to ensure that the joint analysis was valid. We tested the face validity of
our CEA results via the Bucher method. Our results suggest that the 9-week regimen domi-
nated the 12-month regimen as it resulted in a lower cost per patient and more QALYs. The
key driver of the difference was the considerably lower cost of the shorter regimen, as the
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differences in QALYs gained in each arm were not significant. The deterministic sensitivity
analysis suggested that an unrealistically low death rate would be required of the 12-month
arm for it to show greater cost-effectiveness than the 9-week arm. There was however signifi-
cant uncertainty associated with the HR for DDFS and OS for 9-week versus 12-month trastu-
zumab, a key driver of the model, so caution should be taken with this interpretation until
additional research is conducted on the relative effectiveness of 9-week trastuzumab.
NMA can be a powerful tool for synthesising data from multiple trials. This study is, to our
knowledge, the first to use this technique to investigate the relative effectiveness of different tras-
tuzumab durations for determining inputs for a model. We note that a previous pairwise meta-
analysis by Yin et al. [6] reported that using some trastuzumab (grouping 9 weeks’ and 12
months’ together) gave better survival than using no trastuzumab, and the current study goes
further by considering different durations of trastuzumab separately. As with all data synthesis,
the decision over what data to include is critical. What we were unable to test as part of this
model was the impact of a middle ground for treatment regimen, for example 6 months. The
results of the NMA show that inclusion of the only trial to test a 6-month regimen, PHARE,
leads to a significant change in the ranking of treatments according to their impact on adverse
cardiac events when combined with other trial data. It is likely that this is due to the study design
leading to bias in selection of lower-risk patients, particularly in relation to cardiac events.
Pairwise comparisons of 9 weeks vs. zero and 12 months vs. zero give ICERs that agree with
those of other CEAs examining these regimens in different countries which also found that
the 9-week adjuvant trastuzumab with docetaxel followed by anthracycline-based treatment
dominates or is acceptably cost-effective compared to the same regimen without trastuzumab
[36,48,49,50]. Regarding the comparison of 12 months’ vs. zero trastuzumab, Kurian et al. [9]
considered the B31/N9831 trials and found an ICER of US$39,982/QALY (which corresponds
to £32,487 at 2013 prices) using the US perspective. The final appraisal determination by the
ERG [51] for NICE used the HERA trial and found an ICER of £33,000 per QALY gained for
12 months’ vs. zero trastuzumab. Slight variations between ICERs are likely to reflect differ-
ences regarding which trials’ data were used, model structure and inputs, and other modelling
assumptions made. Specifically, the model used by the manufacturer in the ERG report [54]
Fig 3. Cost-effectiveness acceptability curves for the three arms showing which duration is more
cost-effective at different levels of WTP. The heavy tram line indicates the frontier (CEAF).
doi:10.1371/journal.pone.0172731.g003
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was different from the model used here in terms of its structure (the manufacturer’s model
incorporated tunnelling states for cardiac and locoregional recurrence) and input data (the
manufacturer’s model mostly used 2-year data from the HERA study database). The costs, util-
ity values and some transition probabilities used in the manufacturer’s model have not been
made public, so we are unable to offer any further explanation for the difference between our
ICER and theirs.
Given the obvious additional cost of longer treatment durations, and with limited evidence
of benefit, more evidence on treatment durations is needed. The currently ongoing SOLD [55]
and Short-HER [56] trials will provide head-to-head data on the effect of different treatment
durations and will provide additional evidence on the impact of different trastuzumab admin-
istration durations in terms of OS and (D)DFS. SOLD (Synergism Or Long Duration study) is
a Phase 3 randomised controlled trial (RCT) that has enrolled 2,168 patients in Finland and
compares 9 weeks’ adjuvant trastuzumab (either weekly or 3-weekly) given concomitantly
with docetaxel (i.e. the same as the docetaxel subgroup in the short arm of the FinHer trial), to
the same regimen followed by trastuzumab monotherapy up to 1 year. The Short-HER trial is
a Phase 3 non-inferiority trial to test whether the 12-month duration can be reduced to 3
months without loss of efficacy. It is possible that the benefit derived from short treatment reg-
imens is partly due to early administration of trastuzumab concomitantly with taxane before
any other chemotherapy is given[28]. If this is the case, this advantage might be lost in the
3-month arm of the Short-HER trial. Further cost-effectiveness analysis should be undertaken
in the future using the results of these two trials, focusing on the question of optimal duration
of trastuzumab and its impact on costs and QALYs.
Limitations of this CEA include the large uncertainties in utility values and survival rates,
which lead to significant variation in the numbers of QALYs available to each arm, and there-
fore variations in the NMBs for each arm. Also, only three disease states are used, implying that
locoregional recurrence has similar costs and utilities to those of the disease-free state. It should
also be noted that the short-duration trials were not designed to be confirmatory trials regarding
trastuzumab duration, hence their small patient numbers: the FinHer trial has 112 patients in
the trastuzumab arm (54 of which are included in our CEA due to our exclusion of the vinorel-
bine arm) and the E2198 feasibility trial has 115 patients in the 10-week arm and 112 in the
14-month arm (see Table 1). As a result, limited conclusions can be drawn about the strength of
their findings. No subgroup analyses (e.g. by hormone status) have been attempted, since pub-
lished trial data are not reported at a sufficiently disaggregated level to enable this.
Conclusions
This is, to our knowledge, the first multi-arm analysis that compares 9 weeks’ and 12 months’
adjuvant trastuzumab treatment (although previous studies have investigated each regimen
separately in comparison with zero trastuzumab [48,50]). It is also the first network meta-anal-
ysis comparing more than two different non-zero durations of trastuzumab. This study adds
to a growing body of evidence that addresses the important issue of optimal trastuzumab treat-
ment regimens in early breast cancer [11]. It supports further investigation of the hypothesis
that shorter regimens may cost less and may potentially result in equivalent, if not better, clini-
cal outcomes than the currently approved 12-month duration. The NMA, Bucher indirect
comparison, and previously published E2198 head-to-head comparison [20] all show that a
short 9- or 10-week regimen could potentially be as effective as a 12- or 14-month regimen in
purely clinical terms; DDFS, DFS and OS all seem to be the same under the 9-week regimen as
they are for the one-year regimen, with evidence of reduced cardiotoxicity. There is still signifi-
cant uncertainty in the results though meaning that further research is warranted.
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We found that the 9-week regimen dominated the 12-month regimen in cost-effectiveness
terms, but this is based on very little evidence because we had to drop six out of eight studies’
results as their data had not been collected and/or presented in a way that allowed comparison.
Specifically, we could not include results from the only other short-duration trial, E2198, in
our CEA model due to differences in endpoint reporting, and we could not include a 6-month
arm due to PHARE’s late randomisation point. All trial study teams have a responsibility to
their patients and to the wider public to design their trials such that the results are as compara-
ble as possible to other work, and we suggest that these factors should be taken into close con-
sideration when designing and reporting studies.
Future studies with short and medium treatment durations and more comparable trial
designs and reporting could be incorporated into our cost-effectiveness model at a later stage,
to allow for the inclusion of trastuzumab regimens of short and medium duration among com-
pared treatment strategies.
Supporting information
S1 Fig. Gantt chart showing various design and reporting aspects of all arms from all 8 tri-
als of adjuvant trastuzumab in early breast cancer.
(DOCX)
S2 Fig. Probabilities and cumulative probabilities for each treatment type. The left-hand
column of plots gives the probability of each regimen being ranked in each position, i.e. first,
second or third in terms of each event type. The right-hand column shows the cumulative
probabilities. The area under the curve (AUC) for the cumulative probability plots is equal to a
maximum value of 1 if the regimen is unequivocally the best for that event type, and 0 if it is
the worst.
(DOCX)
S3 Fig. Plane showing the PSA results for the absolute costs and QALYs for each of the
three arms. The three red dots indicate the mean costs and QALYs for each arm.
(DOCX)
S1 Table. Inputs for all parameters, showing the base case, lower and upper bounds, and
the type of prior distribution used in the PSA.
(DOCX)
S2 Table. Lifetime horizon probabilistic (n = 5,000) net monetary benefit (WTP = £30,000/
QALY), total cost and total QALYs per patient per arm (mean and 95% CI) for the two
individual 12-month arms of the BCIRG006 study.
(DOCX)
Acknowledgments
The corresponding author would like to thank Elizabeth Clarke for funding the course fees for
the MSc which led to this work. We would also like to thank the Health Economists’ Study
Group Summer 2016 meeting attendees for their helpful comments, as well as anonymous
peer reviewers for their insightful suggestions.
Author Contributions
Conceptualization: CSC RMH IS VSS.
Formal analysis: CSC.
Multi-arm CEA of different durations of trastuzumab in early breast cancer
PLOS ONE | DOI:10.1371/journal.pone.0172731 March 1, 2017 16 / 19
Methodology: CSC RMH IS VSS.
Project administration: CSC.
Supervision: CSC RMH IS VSS.
Validation: CSC.
Visualization: CSC.
Writing – original draft: CSC.
Writing – review & editing: CSC RMH IS VSS.
References
1. ONS. Cancer Statistics Registrations, England 2014 (First Release). [Online].: Office for National Sta-
tistics; 2014 [cited 2016 May. Available from: http://www.ons.gov.uk/peoplepopulationandcommunity/
healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistration
statisticsengland.
2. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mor-
tality Web-based Report. [Online].; 2014 [cited 2015 May 19. Available from: www.cdc.gov/uscs.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation
of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): p.
177–182. PMID: 3798106
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy
plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2.
NEJM. 2001 March 15; 344: p. 783–792. doi: 10.1056/NEJM200103153441101 PMID: 11248153
5. Hall PS, Cameron DA. Current perspective: trastuzumab. European Journal of Cancer. 2009; 45(1): p.
12–18. doi: 10.1016/j.ejca.2008.10.013 PMID: 19042123
6. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the Adjuvant Treatment of HER2-Positive Early
Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials. PLoS ONE. 2011
June; 6(6): p. e21030. doi: 10.1371/journal.pone.0021030 PMID: 21695277
7. NICE. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107).
[Online].; 2006 [cited 2013 October. Available from: www.nice.org.uk/nicemedia/live/11586/33466/
33466.xls (this is the costing template).
8. Perez EA, Rodeheffer R. Clinical Cardiac Tolerability of Trastuzumab. Journal of Clinical Oncology.
2004 January; 22(2): p. 322–329. doi: 10.1200/JCO.2004.01.120 PMID: 14722042
9. Kurian AW, Newton Thompson R, Gaw AF, Arai S, Ortiz R, Garber AM. A Cost-Effectiveness Analysis
of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer. Journal of Clinical
Oncology. 2007; 25: p. 634–641. doi: 10.1200/JCO.2006.06.3081 PMID: 17308268
10. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regi-
mens for early breast cancer. Cochrane Database of Systematic Reviews. 2012;(4): p. CD006243. doi:
10.1002/14651858.CD006243.pub2 PMID: 22513938
11. Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive
breast cancer: Delivery, duration and combination therapies. The Breast. 2013; 22: p. S152–S155. doi:
10.1016/j.breast.2013.07.029 PMID: 24074778
12. NICE. Clinical Guidance: Early and locally advanced breast cancer: Diagnosis and treatment. [Online].;
2009 [cited 2015 January. Available from: http://publications.nice.org.uk/early-and-locally-advanced-
breast-cancer-cg80/research-recommendations.
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A. Trastuzumab after adjuvant chemo-
therapy in HER2-positive breast cancer. New England Journal of Medicine. 2005; 353: p. 1659–1672.
doi: 10.1056/NEJMoa052306 PMID: 16236737
14. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-Year Follow-Up
of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor
2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of
Clinical Oncology. 2011; 29(25): p. 3366–3373. doi: 10.1200/JCO.2011.35.0868 PMID: 21768458
15. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer JCE, et al. Trastuzumab Plus Adjuvant
Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint
Multi-arm CEA of different durations of trastuzumab in early breast cancer
PLOS ONE | DOI:10.1371/journal.pone.0172731 March 1, 2017 17 / 19
Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. 2014;
32: p. 3744–3752. doi: 10.1200/JCO.2014.55.5730 PMID: 25332249
16. Perez EA, Suman VJ, Davidson NE, Gralow J, Kaufman PA, Ingle JN, et al. Results of chemotherapy
alone, with sequential or concurrent addition of trastuzumab in the NCCTG N9831 HER2-positive adju-
vant breast cancer trial. Cancer Research. 2010;(70): p. 5640.
17. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant Docetaxel or
Vinorelbine with or without Trastuzumab for Breast Cancer. New England Journal of Medicine. 2006;
354: p. 809–820. doi: 10.1056/NEJMoa053028 PMID: 16495393
18. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclo-
phosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments
of breast cancer: Final results of the FinHer Trial. Journal of Clinical Oncology. 2009; 27: p. 5685–5692.
doi: 10.1200/JCO.2008.21.4577 PMID: 19884557
19. Sledge GW, O’Neill A, Thor A, Kahanic SP, Zander PJ, Davidson N. Abstract 2075: Adjuvant trastuzu-
mab: long-term results of E2198. In Breast Cancer Research and Treatment, Special Issue, 29th
Annual San Antonio Breast Cancer Symposium; 2006.
20. Schneider BP, O’Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, et al. Pilot trial of paclitaxel-trastu-
zumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research
group (E2198). British Journal of Cancer. 2015 December; 113: p. 1651–1657. doi: 10.1038/bjc.2015.
405 PMID: 26625004
21. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in
HER2-Positive Breast Cancer. The New England Journal of Medicine. 2011 October; 365(14): p.
1273–83. doi: 10.1056/NEJMoa0910383 PMID: 21991949
22. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients
with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial. Journal of Clinical
Oncology. 2009 December; 27(36): p. 6129–6134. doi: 10.1200/JCO.2009.23.0946 PMID: 19917839
23. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of
adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised
phase 3 trial. Lancet Oncology. 2013; 14: p. 741–748. doi: 10.1016/S1470-2045(13)70225-0 PMID:
23764181
24. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Lin-
ear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.
2011 last updated April 2014.
25. DerSimonian R, Laird N. Meta-Analysis in Clinical Trials. Controlled Clinical Trials. 1986; 7: p. 177–
188. PMID: 3802833
26. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining
results from several studies in meta-analysis. In Egger M, Davey Smith G, Altman DG, editors. System-
atic Reviews in Health Care: Meta-Analysis in Context. 2nd ed.: BMJ; 2001.
27. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis:
many names, many benefits, many concerns for the next generation evidence synthesis tool. Research
Synthesis Methods. 2012; 3: p. 80–97. doi: 10.1002/jrsm.1037 PMID: 26062083
28. Petrelli F, Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast
cancer: the sooner the better. Medical Oncology. 2012; 29: p. 503–510. doi: 10.1007/s12032-011-
9897-9 PMID: 21400217
29. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al. 2 years ver-
sus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, rando-
mised controlled trial. Lancet. 2013; 382: p. 1021–1028. doi: 10.1016/S0140-6736(13)61094-6 PMID:
23871490
30. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential Versus
Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology.
2011 December; 29(34): p. 4491–4497. doi: 10.1200/JCO.2011.36.7045 PMID: 22042958
31. White IR. Multivariate random-effects meta-analysis. Stata Journal. 2009; 9(1): p. 40–56.
32. White IR. Network meta-analysis. Stata Journal. 2015; 15(4): p. 951–985.
33. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastu-
zumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lan-
cet. 2007; 369: p. 29–36. doi: 10.1016/S0140-6736(07)60028-2 PMID: 17208639
34. Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Spackman E, et al. Aflibercept in combi-
nation with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer
which has progressed following prior oxaliplatin-based chemotherapy: A Single Technology Appraisal.
Multi-arm CEA of different durations of trastuzumab in early breast cancer
PLOS ONE | DOI:10.1371/journal.pone.0172731 March 1, 2017 18 / 19
[Online].: CRD and CHE Technology Assessment Group; 2013. Available from: http://www.nets.nihr.
ac.uk/__data/assets/pdf_file/0003/82632/ERGReport-11-80-01.pdf.
35. ONS. Interim life tables England and Wales 2012–2014.; 2015.
36. Purmonen TT, Pa¨nka¨la¨inen E, Turunen JHO, Asseburg C, Martikainen FA. Short-course adjuvant trastu-
zumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information anal-
ysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncologia. 2011; 50: p. 344–352.
37. Hall PS, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron DA. Updated Cost-Effectiveness Anal-
ysis of Trastuzumab for Early Breast Cancer, A UK Perspective Considering Duration of Benefit, Long-
Term Toxicity and Pattern of Recurrence. Pharmacoeconomics. 2011; 29(5): p. 415–432. doi: 10.2165/
11588340-000000000-00000 PMID: 21504241
38. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in Patients
With Metastatic Recurrent Breast Cancer After Adjuvant Chemotherapy. Cancer. 2013; 119: p. 1140–
8. doi: 10.1002/cncr.27819 PMID: 23065954
39. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Review of Pharma-
coeconomics Outcomes Research. 2010; 10(5): p. 553–556. doi: 10.1586/erp.10.65 PMID: 20950071
40. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of
life data acquired in the baseline phase of the CARE-HF study. European Journal of Heart Failure.
2005; 7: p. 243–251. doi: 10.1016/j.ejheart.2005.01.012 PMID: 15701474
41. Ara R, Wailoo A. NICE DSU Technical Support Document 12: The use of health state utility values in
decision models. School of Health and Related Research, University of Sheffield, UK; 2011.
42. PSSRU. HCHS Pay and Prices Index.; 2015.
43. NICE. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab. Evidence sum-
maries: new medicines.; 2013.
44. Blackstone EA, Fuhr JP Jr. The Economics of Biosimilars. American Health & Drug Benefits. 2013; 6
(8): p. 469–478.
45. NICE. Guide to the methods of technology appraisal. [Online].; 2013 [cited 2015 January. Available
from: http://publications.nice.org.uk/pmg9.
46. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in
health economic evaluation. Oxford: Oxford University Press; 2006.
47. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effective-
ness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected
value of perfection information (EVPI). Value in Health. 2008 Sep-Oct; 11(5): p. 886–897. doi: 10.1111/
j.1524-4733.2008.00358.x PMID: 18489513
48. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost–effectiveness of trastuzumab in the
adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trials.
Annals of Oncology. 2007; 18: p. 1493–1499. doi: 10.1093/annonc/mdm185 PMID: 17761705
49. Millar JA, Millward MJ. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast can-
cer: a lifetime model. Pharmacoeconomics. 2007;(25): p. 429–442.
50. Neyt M, Huybrechts M, Hulstaert F. Trastuzumab in early stage breast cancer: A cost-effectiveness
analysis for Belgium. Health Policy. 2008;(87): p. 146–159.
51. NICE. Final Appraisal Determination–Trastuzumab for the adjuvant treatment of early-stage HER2-pos-
itive breast cancer.; 2006.
52. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzu-
mab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-
year follow-up of a randomised controlled trial. Lancet Oncology. 2011; 12: p. 236–244. doi: 10.1016/
S1470-2045(11)70033-X PMID: 21354370
53. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons
in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology. 1997; 50(6): p. 683–
691. PMID: 9250266
54. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive
women: a single technology appraisal. Health Technology Assessment. 2009; 13(suppl 1): p. HTA 05/
51/01.
55. The Synergism Or Long Duration (SOLD) Study (clinicaltrials.gov ID: NCT00593697). [Online]. [cited
2013 December. Available from: http://clinicaltrials.gov/show/NCT00593697.]
56. Guarneri V, Frassoldati A, Bruzzi P, D’Amico R, Belfiglio M, Molino A, et al. Multicentric, Randomized
Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of
Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial; NCT00629278). Clinical
Breast Cancer. 2008; 8(5): p. 453–456. doi: 10.3816/CBC.2008.n.056 PMID: 18952561
Multi-arm CEA of different durations of trastuzumab in early breast cancer
PLOS ONE | DOI:10.1371/journal.pone.0172731 March 1, 2017 19 / 19
